|
| | Dolutegravir Impurity C Basic information |
| Product Name: | Dolutegravir Impurity C | | Synonyms: | Dolutegravir Impurity 20;(4R,12aS)-N-(2,4-difluorobenzyl)-7-ethoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:;Dolutegravir Impurity 23;(4R,12aS)-N-(2,4-difluorobenzyl)-7-ethoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1'',2'':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;Dolutegravir Impurity 32;2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-7-ethoxy-3,4,6,8,12,12a-hexahydro-4-methyl-6,8-dioxo-, (4R,12aS)-;Syringaresinol Impurity 1(Syringaresinol Diglucoside) | | CAS: | 1802141-49-6 | | MF: | C22H23F2N3O5 | | MW: | 447.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1802141-49-6.mol |  |
| | Dolutegravir Impurity C Chemical Properties |
| Boiling point | 688.1±55.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | pka | 10.71±0.40(Predicted) |
| | Dolutegravir Impurity C Usage And Synthesis |
| Uses | O-Ethyl Dolutegravir is an impurity of Dolutegravir (D528800), which is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. |
| | Dolutegravir Impurity C Preparation Products And Raw materials |
|
